The Effect of Blood Carboxyhemoglobin Levels on NF-kB, NRF2 and PGC-1α During Low-flow and Normal-flow Anesthesia

NCT07352826 | Recruiting DMC

• 1 other identifier: B.30.2.YYU.0.01.00.00/91
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that exerts diverse biological effects across tissues and organs. At high concentrations, it is recognized as toxic because of harmful effects such as tissue hypoxia, oxidative stress, peroxynitrite formation, inflammation, apoptosis, and immune damage. However, the endogenous production of CO suggests that it may confer protective mechanisms to the host. These protective effects include inhibition of platelet activation, smooth muscle relaxation, vasoactive properties, anti-inflammatory and anti-apoptotic actions, and beneficial influences on neurotransmission. Despite its toxic potential, low-concentration endogenous CO may provide protection linked to the body's defense mechanisms. In this study, we aimed to investigate the anti-apoptotic effects of carbon monoxide at low concentrations. To this end, the relationships between COHb levels and plasma levels of NF-κB, NRF2, and PGC-1α were analyzed statistically.

Conditions

Anesthesia

Keywords

low flow anesthesia; COHb; NF-kB; NRF2; PGC-1 alpha

Outcome Measures

Primary Outcomes (4)

• Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia

  COHb concentrations

  24 HOUR

• Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia

  NF-kB concentrations

  24 HOUR

• Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi

  NRF2 concentrations

  24 HOUR

• Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi

  PGC-1α concentrations

  24 HOUR

Study Arms (4)

COHb

EXPERIMENTAL

Behavioral: low-flow anasthesia; Behavioral: Normal akımlı anestezi

TAS

EXPERIMENTAL

Behavioral: low-flow anasthesia; Behavioral: Normal akımlı anestezi

TOS

EXPERIMENTAL

Behavioral: low-flow anasthesia; Behavioral: Normal akımlı anestezi

HIF 1a

EXPERIMENTAL

Behavioral: low-flow anasthesia; Behavioral: Normal akımlı anestezi

Interventions

low-flow anasthesia BEHAVIORAL

In Group LF, FGF will then be maintained at 0.6 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1

COHb; HIF 1a; TAS; TOS

Normal akımlı anestezi BEHAVIORAL

In Group NF, FGF will be maintained at 2 L/min (O₂ 50%, air 50%) with desflurane adjusted to maintain MAC = 1..

COHb; HIF 1a; TAS; TOS

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• aged 18-70 years
• classified as ASA I
• scheduled for inhalational anesthesia lasting ≥2 hours

You may not qualify if:

• Patients with cardiovascular disease, respiratory system disease, hepatic or renal disease
• pregnant or breastfeeding women
• trauma patients
• those undergoing emergency surgery
• procedures lasting \<2 hours
• those receiving intraoperative blood transfusion
• smokers
• individuals who decline participation

Sponsors & Collaborators

• Ataturk Training and Research Hospital: lead

Study Sites (1)

Veysel

Erzurum, Turkey (Türkiye)

RECRUITING

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, CARE PROVIDER
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 15, 2025
• First Posted: January 20, 2026
• Study Start: February 20, 2026
• Primary Completion (Estimated): May 31, 2026
• Study Completion (Estimated): August 31, 2026
• Last Updated: January 20, 2026

Record last verified: 2026-01

Locations

TU (1)